Skip to main content

Keros Therapeutics, Inc.

KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001664710

In the last 90 days, Keros Therapeutics, Inc. insiders filed 1 open-market purchase and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Keros Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $10.3K in total
Open-market sells
4 filings
4 insiders, $101.1K in total
Insiders trading
5
Net value
−$90.9K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Keros Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Keros Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Tanini AnnitaCorp. Controller & VP, Finance45,144Aug 20, 20261
Lerner Lorena RaquelChief Scientific Officer27,559Aug 20, 20263
Cho EstherChief Legal Officer35,770Aug 20, 20263
Newton Charles W.Director12,114Aug 20, 20263
Bienaime Jean JacquesDirector19,592Aug 19, 20267
Prener AnneDirector13,786Jul 6, 20261
Farzan NimaDirector9,767Jun 8, 20262
Knowles JuliusDirector10,958Jun 8, 20263
Gray Mary AnnDirector12,392Jun 5, 20261
Seth AlpnaDirector12,392Jun 5, 20262
Seehra JasbirCHIEF EXECUTIVE OFFICER440,708Apr 6, 20264
Regnante KeithCHIEF FINANCIAL OFFICER39,261Feb 26, 20262
OrbiMed Advisors LLCDirector45,057IndirectDec 18, 20251
OrbiMed Capital GP VII LLCDirector45,057IndirectDec 18, 20251
OrbiMed Genesis GP LLCDirector45,057IndirectDec 18, 20251
Gordon Carl LDirector45,057IndirectDec 18, 20251
Kariv TomerDirector, 10% Owner0IndirectOct 17, 20250
Nussbaum RanDirector, 10% Owner0IndirectOct 17, 20250
Pontifax (Cayman) IV L.P.10% Owner0IndirectOct 17, 20250
Pontifax (China) IV L.P.10% Owner0IndirectOct 17, 20250
Pontifax (Israel) IV, L.P.10% Owner0IndirectOct 17, 20250
Pontifax Management 4 G.P. (2015) Ltd.10% Owner0IndirectOct 17, 20250
Pontifax Late Stage Fund L.P.10% Owner0IndirectOct 17, 20250
Pontifax Late Stage GP Ltd.10% Owner0IndirectOct 17, 20250
ADAR1 Partners, LP10% Owner0IndirectOct 15, 20250
Schneeberger Daniel10% Owner0IndirectOct 15, 20250
ADAR1 Capital Management GP, LLC10% Owner0IndirectOct 15, 20250
ADAR1 Capital Management, LLC10% Owner0IndirectOct 15, 20250
Rovaldi ChristopherChief Operating Officer60,000Feb 19, 20250
Chyung Yung H.Chief Medical Officer44,000Feb 19, 20250
Cooper Simon PeterCHIEF MEDICAL OFFICER–Feb 15, 20240
Lachey JenniferChief Scientific Officer95,100Jul 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2026 (view filing)4:10 PM ETAug 182 daysTanini AnnitaCorp. Controller & VP, FinanceSSale−1.22K$10.29−$12.6K−2.6%45.1K after
Aug 20, 2026 (view filing)4:10 PM ETAug 182 daysLerner Lorena RaquelChief Scientific OfficerSSale−3.57K$10.29−$36.7K−11.5%27.6K after
Aug 20, 2026 (view filing)4:10 PM ETAug 182 daysCho EstherChief Legal OfficerSSale−4.49K$10.29−$46.2K−11.1%35.8K after
Aug 20, 2026 (view filing)4:10 PM ETAug 182 daysNewton Charles W.DirectorSSale−551$10.30−$5.68K−4.4%12.1K after10b5-1
Aug 19, 2026 (view filing)4:10 PM ETAug 172 daysBienaime Jean JacquesDirectorPPurchase+1.00K$10.27+$10.3K+5.4%19.6K after10b5-1
Jul 17, 2026 (view filing)4:10 PM ETJul 152 daysBienaime Jean JacquesDirectorPPurchase+1.00K$10.61+$10.6K+5.7%18.6K after10b5-1
Jun 17, 2026 (view filing)Jun 152 daysBienaime Jean JacquesDirectorPPurchase+1.00K$10.19+$10.2K+6.0%17.6K after10b5-1
Jun 15, 2026 (view filing)Jun 114 daysNewton Charles W.DirectorSSale−550$10.04−$5.52K−4.2%12.7K after10b5-1
Jun 8, 2026 (view filing)Jun 44 daysKnowles JuliusDirectorSSale−2.63K$10.73−$28.2K−19.3%11.0K after10b5-1
Jun 8, 2026 (view filing)Jun 44 daysFarzan NimaDirectorSSale−2.63K$10.73−$28.2K−21.2%9.77K after10b5-1
Jun 5, 2026 (view filing)Jun 41 daySeth AlpnaDirectorSSale−2.63K$10.72−$28.1K−21.2%9.77K after10b5-1
May 19, 2026 (view filing)May 154 daysBienaime Jean JacquesDirectorPPurchase+1.00K$10.58+$10.6K+11.8%9.45K after10b5-1
Apr 17, 2026 (view filing)Apr 152 daysBienaime Jean JacquesDirectorPPurchase+1.00K$11.70+$11.7K+13.4%8.45K after10b5-1
Mar 11, 2026 (view filing)Mar 92 daysBienaime Jean JacquesDirectorPPurchase+2.00K$11.21+$22.4K+36.7%7.45K after10b5-1
Feb 20, 2026 (view filing)Feb 182 daysCho EstherSVP, General CounselSSale−4.75K$16.35−$77.6K−10.7%39.8K after
Feb 20, 2026 (view filing)Feb 182 daysLerner Lorena RaquelChief Science OfficerSSale−3.87K$16.35−$63.3K−11.1%31.1K after
Feb 20, 2026 (view filing)Feb 191 daySeehra JasbirCHIEF EXECUTIVE OFFICERSSale−7.01K$16.17−$113.4K−1.8%385.7K after
Feb 20, 2026 (view filing)Feb 182 daysRegnante KeithCHIEF FINANCIAL OFFICERSSale−4.74K$16.35−$77.5K−10.8%39.3K after
Oct 17, 2025 (view filing)5:53 PM ETOct 152 daysKariv Tomer and 7 othersDirector, 10% OwnerSSaleCommon Stock, $0.0001 par value per share−4.79M$17.75−$85.0M−100.0%0 after4 lots
Oct 15, 2025 (view filing)1:24 PM ETOct 15Same dayADAR1 Partners, LP and 3 others10% OwnerSSale−5.39M$17.75−$95.7M−100.0%0 after3 lots
Apr 11, 2025 (view filing)9:57 PM ETApr 92 daysADAR1 Partners, LP and 3 others10% OwnerPPurchase+934.3K$10.13+$9.46M+27.0%4.39M after5 lots
Jan 24, 2025 (view filing)Jan 4, 2024386 daysRegnante KeithCHIEF FINANCIAL OFFICERSSale−40.0K$45.29−$1.81M−100.0%0 afterAmended
Aug 15, 2024 (view filing)5:01 PM ETAug 132 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−250.0K$44.01−$11.0M−67.7%119.5K after2 lotsDuplicate filing
Aug 15, 2024 (view filing)Aug 132 daysGordon Carl LDirectorSSale−250.0K$44.01−$11.0M−67.7%119.5K after2 lots
Jun 12, 2023 (view filing)Jun 8-94 daysRegnante KeithChief Financial OfficerSSale−40.0K$46.61−$1.86M−100.0%0 after5 lots10b5-1
Jan 20, 2023 (view filing)Apr 13, 20201,012 daysLateKnowles JuliusDirectorPPurchase+1.19K$20.98+$25.0KNew position1.19K after
Jul 19, 2022 (view filing)4:40 PM ETJul 154 daysLachey JenniferChief Scientific OfficerSSale−46.0K$30.00−$1.38M−32.6%95.1K after
Jul 15, 2022 (view filing)4:40 PM ETJul 132 daysLachey JenniferChief Scientific OfficerSSale−1.92K$30.00−$57.5K−2.0%95.1K after
May 13, 2022 (view filing)4:37 PM ETMay 112 daysLachey JenniferChief Scientific OfficerSSale−5.30K$41.90−$222.0K−5.8%85.7K after5 lots
Apr 13, 2022 (view filing)4:36 PM ETApr 112 daysLachey JenniferChief Scientific OfficerSSale−5.30K$62.77−$332.7K−5.8%85.7K after4 lots
Apr 8, 2022 (view filing)Apr 62 daysRovaldi ChristopherChief Operating OfficerSSale−1.73K$65.00−$112.3K−100.0%0 after
Apr 6, 2022 (view filing)4:49 PM ETApr 42 daysLachey JenniferChief Scientific OfficerSSale−7.95K$60.00−$477.0K−8.5%85.7K after
Apr 5, 2022 (view filing)Apr 14 daysRovaldi ChristopherChief Operating OfficerSSale−864$57.49−$49.7K−100.0%0 after5 lots
Mar 15, 2022 (view filing)4:37 PM ETMar 114 daysLachey JenniferChief Scientific OfficerSSale−2.65K$53.38−$141.4K−3.0%85.7K after3 lots
Feb 15, 2022 (view filing)4:26 PM ETFeb 114 daysLachey JenniferChief Scientific OfficerSSale−2.65K$52.06−$138.0K−3.0%85.7K after3 lots
Jan 13, 2022 (view filing)4:39 PM ETJan 112 daysLachey JenniferChief Scientific OfficerSSale−2.65K$53.75−$142.4K−3.0%85.7K after3 lots
Jan 7, 2022 (view filing)4:35 PM ETJan 52 daysLachey JenniferChief Scientific OfficerSSale−2.65K$60.00−$159.0K−3.0%85.7K after
Jan 5, 2022 (view filing)Jan 3-52 daysKnowles JuliusDirectorSSale−47.7K$57.84−$2.76M−17.0%232.7K after24 lots
Dec 15, 2021 (view filing)4:48 PM ETDec 13-152 daysLachey JenniferChief Scientific OfficerSSale−2.65K$50.40−$133.6K−3.0%85.7K after4 lots
Dec 3, 2021 (view filing)Dec 1-22 daysKnowles JuliusDirectorSSale−47.7K$54.09−$2.58M−15.9%251.5K after16 lots
Nov 12, 2021 (view filing)4:40 PM ETNov 10-112 daysLachey JenniferChief Scientific OfficerSSale−21.2K$59.91−$1.27M−19.8%85.7K after3 lots
Nov 5, 2021 (view filing)5:06 PM ETNov 41 dayLachey JenniferChief Scientific OfficerSSale−10.6K$50.00−$530.0K−11.0%85.7K after
Nov 3, 2021 (view filing)Nov 1-32 daysKnowles JuliusDirectorSSale−47.7K$42.12−$2.01M−15.0%270.3K after12 lots
Oct 21, 2021 (view filing)Oct 19-202 daysKnowles JuliusDirectorSSale−8.60K$38.20−$328.4K−2.9%289.2K after8 lots
Oct 18, 2021 (view filing)Oct 14-184 daysKnowles JuliusDirectorSSale−26.4K$38.56−$1.02M−8.3%292.6K after12 lots
Oct 5, 2021 (view filing)Oct 1-54 daysKnowles JuliusDirectorSSale−12.7K$40.10−$508.8K−4.0%303.0K after6 lots
Sep 29, 2021 (view filing)Sep 272 daysKnowles JuliusDirectorSSale−95.3K$41.17−$3.92M−23.6%308.0K after6 lots
Jul 6, 2021 (view filing)Jul 1-25 daysKnowles JuliusDirectorSSale−47.7K$41.31−$1.97M−12.1%345.6K after10 lots